



Non-Hodgkin's Lymphoma

Quick Reference Guide

2026

Table of Contents

1. CLINICAL SNAPSHOT	3
HCC/RAF V28 Mapping	4
2. RECOGNITION AND DIAGNOSIS	7
Medicare Part B Covered Screenings and Surveillance (Adult and Geriatric).....	7
Subtle Early Signs in Older Adults (>65)	9
Geriatric Risk Factors	9
Diagnostic Thresholds (Lugano Staging and Risk Stratification)	10
Clues to Dig Deeper	14
Common Oversights	15
Key Differentials in Elderly	16
Comorbidity Screening	17
3. MEAT DOCUMENTATION ESSENTIALS	19
Clinical Documentation Elements	20
Reframing Common Documentation Shortcuts	21
4. TREATMENT AND REFERRAL QUICK GUIDE	22
Therapy Escalation Criteria	22
NCCN-Aligned Treatment by Subtype, Fitness, and Patient Profile	24
Non-Pharmacologic Care and Supportive Interventions	25
Medication Safety and Key Interactions	26
When to Refer	27
Follow-Up Timing	28
Comorbidity Management — Primary Care Role.....	29
Cost-Smart Options	30
Patient Education and Adherence	31
Quality Metrics Tie-In	33
5. CODING REMINDERS AND CASE EXAMPLES	35
Coding Specificity	35
Annual Clinical Review and Confirmation	36
Good Documentation - EHR Tips.....	37
Brief Case Examples	37
REFERENCES	39

1 CLINICAL SNAPSHOT

Definition: Non-Hodgkin lymphoma (NHL) is not a single disease but a heterogeneous group of more than **60** distinct lymphoid malignancies arising from **B-cell, T-cell, or NK-cell lymphocytes**, classified by the 2022 WHO/ICC framework into **indolent** and **aggressive** subtypes with widely divergent natural histories, treatment algorithms, and prognoses.^{1,2} The most clinically important distinction for primary care is **indolent versus aggressive**: a patient with low-burden **follicular lymphoma** on active surveillance and a patient with **diffuse large B-cell lymphoma (DLBCL)** receiving curative-intent chemoimmunotherapy are not experiencing variations of one disease.^{2,3} 'Indolent' **does not mean benign**: follicular lymphoma can undergo **histologic transformation** to DLBCL, a life-threatening event requiring urgent re-biopsy, code update, and treatment escalation; conversely, aggressive DLBCL is **potentially curable** with first-line therapy.^{1,3}

ICD-10 Codes:

NHL is reported across the **C82-C88** range, with three mandatory axes of specificity: histologic subtype, anatomic site (5th character), and disease status (active vs. **in remission**, suffix '**A**').⁴ Follicular lymphoma is **C82.-** (grade I-IIIb plus site); small-cell B-cell lymphoma is **C83.0-**; mantle cell lymphoma is **C83.1-**; DLBCL is **C83.3-** (primary CNS lymphoma **C83.390**); mycosis fungoides is **C84.0-**, Sezary disease **C84.1-**, and peripheral T-cell lymphoma not otherwise specified (PTCL-NOS) **C84.4-**; extranodal marginal zone (MALT) lymphoma is **C88.4-**.⁴ **C85.90** (NHL, unspecified, unspecified site) is a temporary placeholder for **pending pathology only** and must be updated to the confirmed subtype-and-site code.⁴ Use **Z85.72** (personal history of NHL) only **after treatment is complete with no active surveillance**.⁴

Prevalence and Burden: The American Cancer Society estimates approximately **79,320** new NHL cases and **19,970** NHL-related deaths in the United States in 2026, with an overall 5-year relative survival near **74%** (ranging from **~88%** for **stage I** to **~64%** for **stage IV**).⁵ NHL is strongly age-predisposed: more than **half** of all diagnoses occur in adults aged **65 or older**, the median age at DLBCL diagnosis is the **mid-60s** with roughly **30%** of patients older than **75**, and age-adjusted NHL incidence in adults aged 75-84 reaches approximately **110.9 per 100,000** versus **~19 per 100,000** in the overall population.^{3,5,6} The **Global Burden of Disease 2021 analysis** estimated about **306,296** new cases and **158,813** deaths among adults ≥ 65 worldwide, a burden that is rising.^{7,8} This makes NHL one of the **most clinically significant cancers older adults**.⁷

AAVBC Knowledge Hub Premium Content Access

Continue reading your guide
with an AAVBC subscription

[Subscribe Now](#)

Already a subscriber? [Sign in](#)

Limited offer

Basic Membership Free

Includes access to downloadable Quick Reference Guides, mailing list for industry updates/medical information, research toolkits, AAVBC events and so much more!

Cancel at any time